Dexamethasone for severe COVID-19

What the study found

COVID-19 can cause diffuse lung damage, and glucocorticoids may blunt the inflammation that drives progression to respiratory failure. In the RECOVERY trial (New England Journal of Medicine, 2021), hospitalized COVID-19 patients were randomly assigned to oral or intravenous dexamethasone, 6 mg once daily for up to 10 days, or to usual care — 2,104 assigned to dexamethasone and 4,321 to usual care. The primary outcome was 28-day mortality, which was lower with dexamethasone; the benefit was greatest in patients who needed invasive ventilation or supplemental oxygen, and not evident in those needing no respiratory support.

Why it matters

Dexamethasone is a decades-old, inexpensive, widely available steroid. Finding that it reduced deaths in the sickest COVID-19 patients — during a pandemic, in a large randomized design — changed care quickly and cheaply, and illustrated repurposing an old drug against a new disease.

Analysis — the pattern

This reflects a recurring critical-care theme (analysis, not a single-study claim): in severe illness, dampening a harmful immune response — not attacking the pathogen — can be what saves lives, and the effect depends on giving it to the right patients at the right stage. The signal was harm-neutral-to-helpful in severe disease but no benefit earlier.

What is still uncertain

It was an open-label trial within a larger platform. Which patients benefit most, the best dose and timing, and how steroids interact with other therapies and with secondary infections continued to be studied.